Organigram Global AI Stock Analysis
Organigram Global (0OG) AI Stock Analysis
Organigram Global
(Frankfurt:0OG)
No summary available
Organigram Global (0OG) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 116.84M
- Dividend Yield
- ―
- Average Volume (3M)
- 1,382
- Price to Earnings (P/E)
- 1.8
- Beta (1Y)
- 0.80
- Revenue Growth
- 30.51%
- EPS Growth
- 1974.35%
- Country
- Germany
- Employees
- 1,139
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Organigram Global Business Overview & Revenue Model
Company Description
Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and co...
Organigram Global Earnings Call Summary
The call communicated strong operational and financial momentum driven largely by the Sanity acquisition: record revenue, margin expansion, record adjusted EBITDA, and meaningful international diversification. Operational improvements in cultivation and category share gains in Canada reinforce the positive narrative. Key risks include negative free cash flow driven by working capital build, pending EU-GMP certification and tight EU-GMP supply into Germany, earlier vape/pre-roll quality issues in Canada, and U.S. regulatory uncertainty. Net income was materially boosted by non-cash fair value gains, so underlying cash generation and integration-related working capital remain focal concerns. On balance, the positive financial results, strategic diversification, and improving margin trajectory outweigh the liquidity and regulatory challenges discussed.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management guided full‑year fiscal 2026 revenue to exceed $350 million, with adjusted gross margin and adjusted EBITDA expected to meaningfully exceed fiscal 2025 levels; they reiterated Sanity is expected to average ~EUR 25 million of quarterly revenue (Sanity delivered EUR 24.5M since April 15 and EUR 25.5M for the full quarter), international sales now constitute ~35% of consolidated revenue (vs ~10% pre‑acquisition), and they expect Q4 to outperform Q3. They cautioned that working‑capital investments tied to the Sanity integration will result in negative free cash flow for the full year (Q3 free cash flow was an outflow of $3.9M) but forecast positive free cash flow in Q4; Q3 results underpinning the outlook included record net revenue of $105.8M, adjusted gross margin of 37% (+300 bps YoY, +600 bps QoQ), record adjusted EBITDA of $13.4M, cash & equivalents of $11.7M and total liquidity of $49.2M. Management also noted Sanity margins are in line with expectations, Germany demand remains strong with minimal price compression, and that achieving EU‑GMP would meaningfully improve margins going forward.
Organigram Global Peers Comparison
Overall Rating
TSE:CRON83Outperform
TSE:GTII69Neutral
TSE:CURA60Neutral
TSE:ACB51Neutral
TSE:WEED48Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 83Outperform | CAD 1.77B | 21.00 | 5.35% | ― | 54.74% | 60.60% | |
| 69Neutral | CAD 1.92B | 14.38 | 5.30% | ― | 6.44% | 127.50% | |
| 60Neutral | CAD 2.97B | -217.45 | -1.47% | ― | 5.01% | 92.12% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | CAD 463.50M | -5.25 | -15.33% | ― | -22.16% | -30.78% | |
| 48Neutral | CAD 364.19M | -1.06 | -39.36% | ― | 10.67% | 74.14% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:0OG | Organigram Global Inc. | 0.75 | -0.52 | -40.94% | |
| TSE:WEED | Canopy Growth | 0.81 | -0.66 | -44.90% | |
| TSE:ACB | Aurora Cannabis (US) | 7.05 | 1.00 | 16.53% | |
| TSE:CRON | Cronos Group (US) | 4.82 | 1.42 | 41.76% | |
| TSE:CURA | Curaleaf Holdings (Otc) | 11.21 | 2.72 | 32.04% | |
| TSE:GTII | Green Thumb Industries (OTC) | 8.74 | 0.79 | 9.94% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
